Session » Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2383

Analysis of the Use of Anticoagulants and Antiplatelet Agents in Strokes Caused By the Deficiency of Adenosine Deaminase 2

9:00AM-11:00AM: Abstract Number: 2375

Biologic Therapy Modifies Clinical and Laboratory Features of Macrophage Activation Syndrome Associated with Systemic Juvenile Idiopathic Arthritis

9:00AM-11:00AM: Abstract Number: 2381

Canakinumab Monotherapy for the Treatment of Majeed Syndrome. Five-Year Experience

9:00AM-11:00AM: Abstract Number: 2400

Clinical and Treatment Factors Associated with Antibiotic-Refractory Lyme Arthritis in Children

9:00AM-11:00AM: Abstract Number: 2388

Clinical Characterization and Outcomes of Pediatric Chronic Nonbacterial Osteomyelitis

9:00AM-11:00AM: Abstract Number: 2397

Developing a Role for 18f-Flurodeoxyglucose PET/MRI in Pediatric Takayasu Arteritis

9:00AM-11:00AM: Abstract Number: 2379

Effect of Canakinumab Treatment on Health-Related Quality of Life in Patients with Periodic Fever Syndromes

9:00AM-11:00AM: Abstract Number: 2380

Efficacy and Safety of Canakinumab in Patients Aged One to Six Years with Cryopyrin-Associated Periodic Syndromes: Results of an Open-Label, Phase III Extension Study

9:00AM-11:00AM: Abstract Number: 2374

Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study

9:00AM-11:00AM: Abstract Number: 2392

Establishing Quality of Life Content Domains in Pediatric Localized Scleroderma

9:00AM-11:00AM: Abstract Number: 2382

Evaluation of Intestinal Inflammation in Children with FMF

9:00AM-11:00AM: Abstract Number: 2396

Initiation of Dialysis in Pediatric ANCA-Associated Vasculitis

9:00AM-11:00AM: Abstract Number: 2377

Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)

9:00AM-11:00AM: Abstract Number: 2389

Is There a Difference in the Presentation of Diffuse and Limited Subtype in Childhood? Results from the Juvenile Scleroderma Inception Cohort

9:00AM-11:00AM: Abstract Number: 2393

Medication Use in the Juvenile Systemic Sclerosis Inception Cohort. ARE There Differences in the Diffuse and Limited Subset Patients?

9:00AM-11:00AM: Abstract Number: 2406

Mental Health Care for Adolescents with Rheumatologic Conditions: Perspectives from Pediatric Behavioral Health Providers in North America

9:00AM-11:00AM: Abstract Number: 2401

Mucocutaneous Lesions and Recurrent Fevers in Patients with Trisomy 8 Mosaicism and Chromosome 8 Duplication

9:00AM-11:00AM: Abstract Number: 2405

Musculoskeletal Manifestations As Presenting Symptoms of Inflammatory Bowel Disease in Children and Adolescents

9:00AM-11:00AM: Abstract Number: 2394

Patient and Parent Global Assessments of Disease Impact in Pediatric Localized Scleroderma: Correlates of Patient Reported Health-Related Quality of Life and Parent Reported Family Impact Domains

9:00AM-11:00AM: Abstract Number: 2378

Pharmacokinetic and Pharmacodynamic Characteristics of Canakinumab in Patients with Periodic Fever Syndromes: Results from a Phase III Pivotal Umbrella Trial

9:00AM-11:00AM: Abstract Number: 2402

Predictive Value of the History and Labs in Distinguishing Inflammatory from Non-Inflammatory and Mechanical Joint Pain

9:00AM-11:00AM: Abstract Number: 2404

Prevalence of Subclinical Entheseal Involvement in Children and Adolescents with Type 1 Diabetes: A Case Control Study

9:00AM-11:00AM: Abstract Number: 2390

Proposal of Assessment of the Activity of Juvenile Localised Scleroderma. Results of the Consensus Meeting in Hamburg, Germany December 2015

9:00AM-11:00AM: Abstract Number: 2398

Reaching the Masses: A Novel Approach to Pediatric Rheumatology Education Via Tele-Learning

9:00AM-11:00AM: Abstract Number: 2387

Response to Pamidronate Treatment Assessed By Whole Body Magnetic Resonance Imaging in Pediatric Chronic Non-Bacterial Osteomyelitis

9:00AM-11:00AM: Abstract Number: 2386

Role of Pentraxin 3 in Patients with Juvenile Scleroderma

9:00AM-11:00AM: Abstract Number: 2403

Sleep Disruption in Children with Chronic Pain

9:00AM-11:00AM: Abstract Number: 2407

The Descriptive Epidemiology of Acute Rheumatic Fever and Post-Streptococcal Reactive Arthritis in Japan

9:00AM-11:00AM: Abstract Number: 2376

The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review

9:00AM-11:00AM: Abstract Number: 2395

The Performance of the Kobayashi and Egami Scores in Detecting IVIG Resistance in Kawasaki Disease in a Single Centre Canadian Cohort Treated with IVIG and Low Dose Aspirin

9:00AM-11:00AM: Abstract Number: 2391

Update on the Juvenile Systemic Sclerosis Inception Cohort Project. Characteristics of the First 80 Patients at First Assessment

9:00AM-11:00AM: Abstract Number: 2385

Validation of Diary Score for the Assessment of Disease Activity in Candle (Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature) and SAVI (STING associated vasculopathy with onset in Infancy) Patients

9:00AM-11:00AM: Abstract Number: 2384

Variable Clinical Phenotypes and Relation of Interferon Signature with Disease Activity in ADA 2 Deficiency

9:00AM-11:00AM: Abstract Number: 2399

Waning Hepatitis B Immunity Status in a Significant Proportion of Immunocompromised Pediatric Rheumatology and Gastroenterology Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].